Table.

Characteristics of Patients With MLL-SEPT9 Fusion

Case Number	Age (y) and Sex	Diagnosis	MLL- SEPT9 Variant*	Clinical Outcome	Reference
1	10 F	t-AML**	1	NR	(9)
2	24 M	AML M4***	1	Death without achieving remission	(10)
3	4 months F	De novo AML M5	1	Alive >5 years with multiagent chemotherapy followed by cord blood transplant	(10)
4	64 M	De novo AML M4	1	Septic death during relapse after brief chemotherapy- induced remission	(11)
5	8 M	De novo AML M4	3	NR	(5)
6	60 F	De novo AML M5	2	NR	(5)
7	50 F	De novo AML M2	1	NR	(5)
8	61 F	MDS (unclassifiable, then RAEB-I)	3	Clinical response to decitabine, referred for stem cell transplantation	This report

Abbreviations: M, male; F, female; y, years of age; AML, acute myeloid leukemia; t-AML, therapy-related AML; MDS, myelodysplastic syndrome; NR, not reported.

^*See Figure 1B.

^**Following therapy for Hodgkin disease.

^***Patient was previously treated for AML M2 with t(8;21) AML1-ETO fusion.